What is Thymulin?
Thymulin is a thymic peptide whose biological activity depends on zinc. The featured human study examined zinc status and thymulin activity; it was not a trial of thymulin injections.
Biological role or research focus
Zinc status and thymic signaling.
These findings do not establish clinical benefit from injecting thymulin or treating people who are not zinc deficient.
Role reference: Serum thymulin in human zinc deficiency. · 1988 ↗
Names you may encounter
Serum thymic factor · FTS
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Zinc-dependent thymic peptide activity
- Research focus
- Zinc status and thymic signaling
- Featured evidence
- Human physiological study
- Source check
- October 4, 2026
Quick answers
- Is Thymulin FDA approved?
- No. No FDA-approved drug contains Thymulin. FDA lists it in 503A category 3: nominated for compounding without enough supporting information. Source ↗
- Is Thymulin safe?
- Not an approved drug. Studies measure the body's own thymulin; no published human safety studies of giving thymulin were found, so its risks are unknown. Human safety data: none. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Thymulin banned in sport?
- Very likely. The 2026 World Anti-Doping Agency (WADA) Prohibited List does not name it, but it appears to fall under a banned class (S0 Non-approved substances). Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| Zinc status and thymulin activity (1988) | Human physiological study | 14 participants across experimentally induced zinc deficiency, sickle-cell anemia, and other clinical groups. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human physiological study · 1988
Zinc status and thymulin activity
What did this publication test, and what did it find?
- Population / model
- 14 participants across experimentally induced zinc deficiency, sickle-cell anemia, and other clinical groups.
- Study design
- Small physiological comparisons with zinc-related interventions and laboratory restoration experiments.
- Main finding
- Thymulin activity was lower in zinc-deficient settings and was restored with zinc in the reported in-vivo and in-vitro experiments.
- Limits & context
- These findings do not establish clinical benefit from injecting thymulin or treating people who are not zinc deficient.
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
No study naming Thymulin as an intervention was found on ClinicalTrials.gov when we last checked (November 16, 2026). That means no registered human trial, not proof that none has ever been done elsewhere.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Zinc status of Indian children. ↗
The Indian journal of medical research · 1995 Nov · Journal Article, Review
Thymic endocrinology. ↗
Annals of the New York Academy of Sciences · 1998 May 1 · Journal Article, Review
Thymic endocrinology. ↗
International journal of immunopharmacology · 1992 Apr · Journal Article, Review
Zinc: an overview. ↗
Nutrition (Burbank, Los Angeles County, Calif.) · 1995 Jan-Feb · Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, Non-P.H.S., Research Support, U.S. Gov't, P.H.S., Review
Risks & interactions
Not an approved drug. Studies measure the body's own thymulin; no published human safety studies of giving thymulin were found, so its risks are unknown.
No published studies of giving thymulin to people were found. Human research measured natural thymulin activity in zinc deficiency, which cannot define the risks of an administered product.
Unassessed: no human safety data
It isn't approved, so there is no official list of who should avoid it, and no human safety studies have been published. No condition is tagged, but that does not make it safe for anyone. If a condition applies to you, talk to a doctor or pharmacist first.
Who should not use it
There is no official list, because it has never been approved as a medicine. That is not a sign it is safe for anyone: its risks have not been studied enough to know who is most at risk.
Summarized from published studies with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: Serum thymulin in human zinc deficiency (1988) ↗ · Thymic endocrinology (review, 1998) ↗
Safety & what remains unknown
The paper is not an administered-thymulin safety study and cannot define such a preparation’s clinical risk.
Source: Serum thymulin in human zinc deficiency. · 1988 ↗
Evidence boundaries
These findings do not establish clinical benefit from injecting thymulin or treating people who are not zinc deficient.
Source: Serum thymulin in human zinc deficiency. · 1988 ↗
Regulatory status
- U.S. FDA approval
- Not approved
No FDA-approved drug containing this substance found in Drugs@FDA (openFDA data updated 2026-10-07). source - FDA compounding (503A bulk list)
- Category 3 (nominated without enough support)
Listed in 503A category 3 ("Thymulin acetate", nominated without adequate support). source - World Anti-Doping Agency (2026)
- Likely prohibited under a class rule · S0 Non-approved substances
Not named. S0 prohibits (at all times) any pharmacological substance not covered by another section and with no current approval by any government health authority for human therapeutic use; no such approval was found, so it is likely covered. source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Research context & identity
This profile concerns immune-endocrine physiology and zinc-associated laboratory measures, rather than an established immune-boosting product.
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
Seller lab-report checks and prices are available to members. Sign up free
Biology & proposed mechanism
The study tested whether zinc availability affects measured thymulin activity. Restoring a biomarker with zinc is different from demonstrating an effect of administered thymulin.
Questions worth asking
- Did the study test thymulin injections?
- What material, population, and route were actually studied?
- These findings do not establish clinical benefit from injecting thymulin or treating people who are not zinc deficient.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Did the study test thymulin injections?
No. It investigated zinc status and thymulin activity, including zinc-related restoration experiments.
Does the publication verify a supplier’s product?
No. The tested material and a commercial listing need separate identity and batch checks. A research-use disclaimer does not establish clinical suitability.
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
